Growth hormone (GH) is effective in improving height in several conditions. Objective: To describe the evolution of a group of children who received GH in a tertiary center between 2012-2022. Patients and Method: Descriptive, retrospective study. We analyzed the impact on height after GH use with Z -score according to etiology, age at onset and bone age. Patients under 15 years old at baseline and receiving GH for at least 12 months, with diagnoses of GH deficiency (GHD), idiopathic short stature (ISS), small for gestational age (SGA), SHOX Haploinsufficiency (SHOX) and Turner syndrome (TS) were included. Height was expressed as Z -score for age and sex, according to NCHS curves. Results: 145 children received GH. Sixty patients were excluded due to irregular administration, incomplete data, less than 12 months of GH, change of hospital, and associated comorbidities. Seventy-three patients were analyzed, 23 GHD, 15 ISS, 20 SGA, 9 SHOX and 6 TS patients. Significant improvement in height (Z -score for age and sex) was observed in SGA (1.4 +/- 0.8 gain; p < 0.001), GHD (1.1 +/- 1.0; p < 0.001), ISS (1.1 +/- 0.8; p < 0.001) and SHOX (0.8 +/- 0.7; p = 0.007) patients. In TS, a non -statistically significant improvement was observed (0.7 +/- 0.8; p = 0.085). In GHD, onset before 3 years showed a gain of 1.9 +/- 1.1, vs 0.7 +/- 0.6 (p = 0.083) and in ISS onset with bone age less than 9 years increased it by 1.7 +/- 0.5 vs 0.5 +/- 0.5 (p < 0.001). Adverse events: 27/73 (37%) headache, 18/73 (24%) lower extremity pain, 1/73 (1.5%) dizziness, 1/73 (1.5%) scoliosis, 1/73 (1.5%) epiphysiolysis and 1/73 (1.5%) craniopharyngioma recurrence. Conclusions: Children with GHD, ISS, SHOX mutation and SGA significantly improved their height, highlighting in GHD and ISS the importance of early treatment. Treatment was well tolerated in the 5 groups analyzed.